11 recruiting, 6 active not recruiting, 6 completed, 3 unknown. 31 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Recruiting 11, Active not recruiting 6, Completed 6, Unknown 3, Withdrawn 3, Not yet recruiting 2 |
| Phase 1 | 2 | Recruiting 2 |
Follow Endocrine Therapy: new trials by email Literature Review of Endocrine Therapy trials Research Report on Endocrine Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases Culmerciclib, Anlotinib, Endocrine Therapy - HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases | Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2026-08-28 | 2026-08-04 |
| A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Recruiting | University of Washington | 40 | 2025-11-17 | 2026-11-02 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-11-03 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer Stereotactic Body Radiation Therapy (SBRT), Toripalimab, Neoadjuvant Chemotherapy - Breast Cancer | Phase 2 | Recruiting | Xijing Hospital | 27 | 2025-06-05 | 2026-08-14 |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer Alisertib, Endocrine therapy - Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Puma Biotechnology, Inc. | 225 | 2024-11-19 | 2026-10-01 |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers Endocrine Therapy, Biopsy of breast, Neratinib - Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2024-06-11 | 2026-08-19 |
| Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer Dalpiciclib, Endocrine therapy - Early Breast Cancer | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 1163 | 2023-11-17 | 2024-04-02 |
| Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors - Breast Cancer, Advanced Breast Cancer | Phase 2 | Recruiting | Fudan University | 265 | 2023-07-26 | 2024-02-08 |
| Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer Everolimus, Chidamide, Endocrine therapy - HR+/HER2- Advanced Breast Cancer, Targeted Therapy | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 102 | 2023-07-20 | 2023-08-09 |
| Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer Inavolisib, PHESGO, Endocrine therapy - HER2-positive Breast Cancer | Phase 2 | Recruiting | GBG Forschungs GmbH | 170 | 2023-01-02 | 2026-09-11 |
| Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. Tucidinostat, Capecitabine, Endocrine Therapy - Breast Cancer | Phase 2 | Unknown | wang shusen | 73 | 2022-10-03 | 2022-11-04 |
| SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy - Brain Metastases, HR+ Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 31 | 2021-11-30 | 2026-09-28 |
| Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy Hormone Therapy, Stereotactic Body Radiation Therapy - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 165 | 2021-06-23 | 2026-07-17 |
| Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) Pertuzumab and trastuzumab FDC subcutaneous, Paclitaxel, TDM1 - Mammary Cancer | Phase 2 | Not yet recruiting | David Garcia Cinca | 27 | 2020-06-15 | 2020-03-10 |
| Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer tamoxifen, letrozole, anastrozole, or exemestane, Patient reported outcomes - Breast Cancer Female | Phase 2 | Active not recruiting | Shayna Showalter, MD | 84 | 2020-04-07 | 2025-10-22 |
| Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer Endocrine therapy - Breast Neoplasms | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 185 | 2019-07-01 | 2019-07-17 |
| PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) Palbociclib, Endocrine therapy - Breast Cancer, Advanced Breast Cancer | Phase 2 | Completed | MedSIR | 198 | 2019-04-05 | 2023-09-07 |
| Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer Avelumab, Endocrine therapy, Palbociclib - Breast Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 33 | 2018-11-13 | 2026-09-24 |
| MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. Zenocutuzumab, Trastuzumab, Vinorelbine - Breast Cancer Metastatic | Phase 2 | Completed | Merus B.V. | 105 | 2018-01-15 | 2024-03-07 |
Showing 20 of 31. Sign in to see all of them.
Breast Neoplasms (20) · Carcinoma, Lobular (2) · Prostatic Neoplasms (2) · Brain Neoplasms (1) · Carcinoma, Islet Cell (1) · Gastrinoma (1) · Glucagonoma (1) · Insulinoma (1) · Lethal Congenital Contracture Syndrome 2 (1) · Neoplasm Metastasis (1) · Neoplastic Cells, Circulating (1) · Somatostatinoma (1) · Vipoma (1)
M.D. Anderson Cancer Center (2) · SOLTI Breast Cancer Research Group (2) · Burzynski Research Institute (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Dana-Farber Cancer Institute (1) · David Garcia Cinca (1) · Eastern Cooperative Oncology Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fudan University (1) · GBG Forschungs GmbH (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Massachusetts General Hospital (1) · MedSIR (1) · Merus B.V. (1)
United States (15) · China (9) · Spain (7) · France (3) · Germany (3) · United Kingdom (3) · Belgium (2) · Italy (2) · Portugal (2) · Netherlands (1) · Poland (1) · Romania (1) · Slovakia (1) · Slovenia (1)
Aleix Prat, MD, PhD (1) · Amar Kishan (1) · Antonio Llombart, MD, PhD (1) · Arielle Medford, MD (1) · Brigitte Rack, MD (1) · Cesar A. Santa-Maria, MD, MSCI (1) · Christos Sotiriou, MD (1) · Cuizhi Geng, MD (1) · Elizabeth C Reed, MD (1) · Eric A. Strrom, MD, BS (1) · Ernesto Wasserman, MD (1) · Eva Ciruelos, MD (1) · Heather Han, MD (1)
PMID 27289552, PMID 28238593, PMID 29045543, PMID 33369581, PMID 35135810, PMID 37450351, PMID 40294349, PMID 41272386, PMID 41276768, PMID 41672025
2017 (2), 2009 (1), 2014 (1), 2019 (1), P30CA016672 (1), P30CA036727 (1), R01CA273246 (1), R21CA277311 (1)